Emisphere Technologies, Inc. to Hold Conference Call to Discuss Second Quarter 2005 Financial Results

Search Blogs that Mention this News Release

Click this link to view linked Bookmarking Services

Click this link to view linked Blogging Services

Emisphere Technologies, Inc. to Hold Conference Call to Discuss Second Quarter 2005 Financial Results

    TARRYTOWN, N.Y., July 20 /PRNewswire-FirstCall/ -- Emisphere Technologies,
Inc. (Nasdaq: EMIS) will hold a conference call to discuss the Company's
financial results for the quarter ended June 30, 2005. The call will be held
on Thursday, August 4, 2005, beginning at 10:30 a.m. Eastern Time (7:30 a.m.
Pacific). A replay of the call will be accessible approximately two hours
following the end of the call and will be archived through August 11, 2005.

    The live conference call dial-in number is:  800-963-8290 (U.S./Canada)
                                                 973-935-8502 (international)

    To access a replay of the call:              877-519-4471 (U.S./Canada)
                                                 973-341-3080 (international)
                                                 Conference ID: 6206647

    Emisphere will be simultaneously webcasting this teleconference. To access
the live broadcast in listen-only mode, please go to the investor relations
portion of the Company's website at http://www.emisphere.com/ir.asp. Please visit the
site at least five minutes prior to start time for instructions. A replay of
the call will also be available on the Company's website through August 11,
2005.

    About Emisphere Technologies, Inc.
    Emisphere Technologies, Inc. is a biopharmaceutical company pioneering the
oral delivery of otherwise injectable drugs.  Emisphere's business strategy is
to develop oral forms of injectable drugs, either alone or with corporate
partners, by applying its proprietary eligen(R) technology to those drugs or
licensing its eligen(R) technology to partners who typically apply it directly
to their marketed drugs. Emisphere's eligen(R) technology has enabled the oral
delivery of proteins, peptides, macromolecules and charged organics.
Emisphere and its partners have advanced oral formulations or prototypes of
salmon calcitonin, heparin, insulin, parathyroid hormone, human growth hormone
and cromolyn sodium into clinical trials. Emisphere has strategic alliances
with world-leading pharmaceutical companies. For further information, please
visit http://www.emisphere.com.

SOURCE Emisphere Technologies, Inc.

http://www.emisphere.com/ir.asp

http://www.emisphere.com
CONTACT:
Gillian Racine, Associate, Investor Relations
of Emisphere Technologies, Inc., +1-914-593-8332,
gracine@emisphere.com